We report a case of a 66-year-old Caucasian female with a diagnosis of idiopathic orbital inflammatory disease (OID) refractory to azathioprine therapy. The coexistence of diabetes mellitus represented a relative contraindication to chronic prednisone use. After two infusions of rituximab, a chimeric anti-CD20+ antibody, ophthalmic signs and symptoms remarkably improved. To our knowledge, this is the first case of idiopathic OID successfully treated with rituximab.
Savino, G., Battendieri, R., Siniscalco, A., Mandara', E., Mule', A., Petrone, G., Traina, S., Riso, M., Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports, <<RHEUMATOLOGY INTERNATIONAL>>, 2015; (1): 183-188 [http://hdl.handle.net/10807/70295]
Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports
Savino, Gustavo;Battendieri, Remo;Siniscalco, Andrea;Mandara', Erika;Mule', Antonino;Petrone, Gianluigi;Traina, Salvatore;
2015
Abstract
We report a case of a 66-year-old Caucasian female with a diagnosis of idiopathic orbital inflammatory disease (OID) refractory to azathioprine therapy. The coexistence of diabetes mellitus represented a relative contraindication to chronic prednisone use. After two infusions of rituximab, a chimeric anti-CD20+ antibody, ophthalmic signs and symptoms remarkably improved. To our knowledge, this is the first case of idiopathic OID successfully treated with rituximab.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
